Literature DB >> 15084783

Aspirin, NSAIDs, risk of dementia, and influence of the apolipoprotein E epsilon 4 allele in an elderly population.

C Cornelius1, J Fastbom, B Winblad, M Viitanen.   

Abstract

In a cohort study, 1,301 subjects free of dementia at baseline in the Kungsholmen Project were followed up to 6 years. We studied the association between use of aspirin and non-steroidal anti-inflammatory drugs (NSAIDs), incidence of Alzheimer's disease (AD) and overall dementia, and the influence of the apolipoprotein E epsilon4 allele. In stratified analyses, a relative risk (RR) of 1.80 (95% CI 1.14-2.83) for AD was seen, in the apoE epsilon4-negative group using aspirin. This implicates a possible different mechanism of developing AD in this group. We also found a possible protective effect of NSAIDs against AD, since no one who used NSAIDs for around 3 years had developed AD 3 years later. One user developed vascular dementia, and a low point value of risk was seen, however, not significant (RR 0.23; 95% CI 0.03-1.68). This could be due to the small samples in our study, or to comorbidity contributing to the development of dementia in this elderly population. Copyright 2004 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15084783     DOI: 10.1159/000075957

Source DB:  PubMed          Journal:  Neuroepidemiology        ISSN: 0251-5350            Impact factor:   3.282


  26 in total

1.  Neuroinflammatory Cytokines-The Common Thread in Alzheimer's Pathogenesis.

Authors:  W Sue T Griffin; Steven W Barger
Journal:  US Neurol       Date:  2010

Review 2.  Amyloid-modifying therapies for Alzheimer's disease: therapeutic progress and its implications.

Authors:  Meaghan C Creed; Norton W Milgram
Journal:  Age (Dordr)       Date:  2010-04-20

3.  Pain treatment in elderly persons with and without dementia: a population-based study of institutionalized and home-dwelling elderly.

Authors:  Ylva Haasum; Johan Fastbom; Laura Fratiglioni; Ingemar Kåreholt; Kristina Johnell
Journal:  Drugs Aging       Date:  2011-04-01       Impact factor: 3.923

Review 4.  Inflammation in Alzheimer disease-a brief review of the basic science and clinical literature.

Authors:  Tony Wyss-Coray; Joseph Rogers
Journal:  Cold Spring Harb Perspect Med       Date:  2012-01       Impact factor: 6.915

5.  Undertreatment of osteoporosis in persons with dementia? A population-based study.

Authors:  Y Haasum; J Fastbom; L Fratiglioni; K Johnell
Journal:  Osteoporos Int       Date:  2011-04-16       Impact factor: 4.507

6.  Identification and modification of amyloid-independent phenotypes of APOE4 mice.

Authors:  Amanda M DiBattista; Sonya B Dumanis; Joshua Newman; G William Rebeck
Journal:  Exp Neurol       Date:  2016-04-14       Impact factor: 5.330

7.  Frontiers in Alzheimer's disease therapeutics.

Authors:  Jeremy G Stone; Gemma Casadesus; Kasia Gustaw-Rothenberg; Sandra L Siedlak; Xinglong Wang; Xiongwei Zhu; George Perry; Rudy J Castellani; Mark A Smith
Journal:  Ther Adv Chronic Dis       Date:  2011-01-01       Impact factor: 5.091

Review 8.  Can peripheral leukocytes be used as Alzheimer's disease biomarkers?

Authors:  Kavon Rezai-Zadeh; David Gate; Christine A Szekely; Terrence Town
Journal:  Expert Rev Neurother       Date:  2009-11       Impact factor: 4.618

9.  Are NSAIDs useful to treat Alzheimer's disease or mild cognitive impairment?

Authors:  Bruno P Imbimbo; Vincenzo Solfrizzi; Francesco Panza
Journal:  Front Aging Neurosci       Date:  2010-05-21       Impact factor: 5.750

Review 10.  Drug development for Alzheimer's disease: where are we now and where are we headed?

Authors:  Marwan N Sabbagh
Journal:  Am J Geriatr Pharmacother       Date:  2009-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.